Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Change in Account Payables (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Change in Account Payables for 3 consecutive years, with -$829000.0 as the latest value for Q4 2025.

  • Quarterly Change in Account Payables rose 73.42% to -$829000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$3.3 million through Dec 2025, down 118.44% year-over-year, with the annual reading at -$3.3 million for FY2025, 118.44% down from the prior year.
  • Change in Account Payables for Q4 2025 was -$829000.0 at Inhibrx Biosciences, up from -$1.5 million in the prior quarter.
  • The five-year high for Change in Account Payables was $17.4 million in Q2 2024, with the low at -$3.1 million in Q4 2024.
  • Average Change in Account Payables over 3 years is $1.6 million, with a median of -$525000.0 recorded in 2024.
  • Peak annual rise in Change in Account Payables hit 73.42% in 2025, while the deepest fall reached 237.56% in 2025.
  • Over 3 years, Change in Account Payables stood at $2.9 million in 2023, then plummeted by 207.18% to -$3.1 million in 2024, then surged by 73.42% to -$829000.0 in 2025.
  • According to Business Quant data, Change in Account Payables over the past three periods came in at -$829000.0, -$1.5 million, and -$600000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.